Abstract
Hypoactive sexual desire disorder (HSDD) is the most common sexual dysfunction in women, and is characterized by an absence or deficiency of sexual desire accompanied by distress. HSDD affects approximately 10% of women, with a similar prevalence regardless of age or country. Bremelanotide, a melanocortin receptor agonist and an analog of the endogenous neuropeptide α-melanocortin stimulating hormone, is approved for the treatment of acquired, generalized HSDD in premenopausal women. The RECONNECT studies (Studies 301 and 302), which comprised two identically designed, double-blind, randomized, placebo-controlled studies, demonstrated that subcutaneous self-administration of bremelanotide, as needed, significantly improved sexual desire and decreased related personal distress in premenopausal women with HSDD.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call